EMADOC-1700519818-1775423

European Medicines Agency decision

EMA/PE/0000181219

of 6 December 2024

on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate) (Sirturo) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000181219

of 6 December 2024

on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate) (Sirturo) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/55/2011 issued on 4 March 2011, the decision P/0105/2013 issued on 30 April 2013, the decision P/0065/2015 issued on 1 April 2015, the decision P/0371/2016 issued on 4 January 2017, the decision P/0403/2018 issued on 19 December 2018, the decision P/0373/2020 issued on 9 September 2020 and the decision P/0470/2022 issued on 16 November 2022,

Having regard to the application submitted by Janssen-Cilag International NV on 27 June 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Changes to the agreed paediatric investigation plan for bedaquiline (fumarate) (Sirturo), including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 1

This decision is addressed to Janssen-Cilag International NV, Turnhoutseweg 30, 2340 – Beerse, Belgium.

EMADOC-1700519818-1622327
Amsterdam, 18 October 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA/PE/0000181219

Scope of the application

Active substance(s):

Bedaquiline (fumarate)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of multi-drug resistant tuberculosis

Pharmaceutical form(s):

Tablet

Granules

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Janssen-Cilag International NV

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International NV submitted to the European Medicines Agency on 27 June 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/55/2011 issued on 4 March 2011, the decision P/0105/2013 issued on 30 April 2013, the decision P/0065/2015 issued on 1 April 2015, the decision P/0371/2016 issued on 4 January 2017, the decision P/0403/2018 issued on 19 December 2018 and the decision P/0373/2020 issued on 9 September 2020 and the decision P/0470/2022 issued on 16 November 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 19 August 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of multi-drug resistant tuberculosis

2.1.1. Indication(s) targeted by the PIP

Treatment of multi-drug resistant tuberculosis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Granules

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age appropriate formulation
Non-clinical studies	**Study 2 (TMC207-NC119)** Juvenile toxicity study in rats
Clinical studies	**Study 3 (TMC207TBC1002)** Open-label, randomised, crossover study in healthy adult subjects to determine the relative bioavailability of bedaquiline (fumarate) (TMC207) as tablet (for adults) to an age appropriate formulation and to investigate the food effect of the selected paediatric formulation. **Study 4 (TMC207-C211)** Open-label, multicenter, single arm study to evaluate the pharmacokinetics, safety, tolerability and anti-mycobacterial activity of TMC207 in combination with a background regimen (BR) of multi-drug resistant tuberculosis (MDR-TB) medications for the treatment of children and adolescents from birth to less than 18 years of age who have been diagnosed with confirmed or probable MDR-TB.

Extrapolation, modelling and simulation studies	Not applicable.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of multi-drug resistant tuberculosis

Authorised indication(s):

- SIRTURO is indicated for use as part of an appropriate combination regimen in adult and paediatric patients (5 years to less than 18 years of age and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
  - Invented name(s): Sirturo
  - Authorised pharmaceutical form(s): Tablet
  - Authorised route(s) of administration: Oral use
  - Authorised via centralised procedure